From the Food and Drug Administration.
D000998:Antiviral Agents / Q000627:therapeutic use*; D002047:Buprenorphine / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D010330:Patents as Topic; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009292:Narcotic Antagonists; D011994:Recombinant Proteins; D009270:Naloxone; D011092:Polyethylene Glycols; D002047:Buprenorphine; C100416:peginterferon alfa-2a